18FFDG-PET and β-amyloid-PET are established tools for assessing biomarker status in Alzheimer's disease. In this study, we evaluated the potential of early-phase 18Fflorbetaben (FBB) PET as a functional proxy for 18FFDG-PET in preclinical Alzheimer's disease models by examining regional perfusion and glucose metabolism in two transgenic mouse lines. Ninety-two APPPS1 (n = 17), APPSAA (n = 56), and age- and sex-matched wild-type mice (n = 19; 3-12 months, 40% female) underwent static 18FFDG-PET (30-60 min p.i.) and dynamic 18FFBB-PET (0-60 min p.i.). Standardized uptake values were derived for both 18FFDG-PET and 18FFBB-PET for the whole brain and 14 Ma-Benveniste-Mirrione atlas regions. We identified the 1-3 min p.i. time window as optimal, yielding the highest concordance with 18FFDG (R = 0.53, p SAA mice exhibited significant increases in perfusion (both p p = 0.0028; APPSAA: p 18F]FBB-PET not only mirrors 18FFDG-PET-derived metabolic changes but also enables a single-scan assessment of β-amyloid pathology and brain function, thereby reducing the number of required scans and potentially the number of animals per study, and strengthening the translational value of preclinical PET research.
Gröger et al. (Tue,) studied this question.